drugset

drugset / Trial / NCT03070548

A Study of Talazoparib in Patients With Advanced Solid Tumors

NCT03070548 ↗

Phase 1 Completed 6 enrolled Pfizer Medivation, Inc. · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the mass balance of talazoparib after a single dose of talazoparib.

Timeline

Start: 2016-09
Primary completion: 2017-06
Completion: 2017-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Talazoparib	Small molecule	1 mg	—

Indications